[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
July 2000

Treatment of McArdle Disease

Arch Neurol. 2000;57(7):923-924. doi:10.1001/archneur.57.7.923

WE ARE approaching the 50th anniversary of the classical description by Brian McArdle1 of the metabolic myopathy that bears his name. It was recognized 40 years ago that the symptoms of McArdle disease—exertional muscle fatigue, pain, cramps (contractures), and myoglobinuria—were due to deficiency of the muscle form of glycogen phosphorylase, and thus were related specifically to the unavailability of muscle glycogen as a source of energy for muscle contraction.2,3 In the last few years, understanding of the molecular pathogenesis of McArdle disease has advanced with the description of approximately 20 different mutations in the phosphorylase gene on chromosome 11.4 However, treatment of McArdle disease has lagged and remains an important clinical challenge.

First Page Preview View Large
First page PDF preview
First page PDF preview
×